Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

ia (Ph+ CML) in chronic phase. The effectiveness of Tasigna for this indication is based on major molecular response and cytogenetic response rates at 12 months. The study is ongoing and further data will be required to determine long-term outcome.

Tasigna® (nilotinib) 200 mg capsules is also approved in more than 90 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Gleevec. The effectiveness of Tasigna for this indication is based on hematologic and cytogenetic response rates.

TASIGNA BOXED WARNING and Additional Important Safety InformationTASIGNA (nilotinib) prolongs the QT interval. Sudden deaths have been reported in patients receiving TASIGNA. TASIGNA should not be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be corrected prior to TASIGNA administration and should be periodically monitored. Drugs known to prolong QT interval and strong CYP3A4 inhibitors should be avoided. Patients should avoid food 2 hours before and 1 hour after taking dose. A dose reduction is recommended in patients with hepatic impairment.

ECGs should be obtained to monitor the QTc at baseline, 7 days after initiation and periodically thereafter, as well as following any dose adjustments.

  • Treatment with TASIGNA can cause Grade 3/4 thrombocytopenia, neutropenia and anemia. Complete blood counts should be performed every 2 weeks for the first 2 months and then monthly thereafter.

  • Caution is recommended in patients with a history of pancreatitis.

  • The use of TASIGNA may result in elevations in bilirubin, AST/ALT and alkaline phosphatase.

  • TASIGNA can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia and hyponatremia (see Boxed WARNING).

  • The concomitant use of strong CYP3A4 inhibitors or anti-arrhythmic drugs (includ
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/3/2015)... 2015 Research and ... of the "Investigation Report on China,s Progesterone ... The clinical demand for steroid drug is ... good efficacy especially its extended use in regulating ... years. Progesterone, a natural progestogen produced by ...
    (Date:9/3/2015)... 03, 2015 Research and ... the "Investigation Report on China,s Raloxifene Market, 2010-2019" ... the statistics, over 200 million people suffer from osteoporosis ... in China , 50% have low ... among women aged 60 and above. Raloxifene (raloxifene ...
    (Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/sd9xxh/radiology ) ... Systems Market by Type, Deployment Mode, End User and ... report to their offering. The ... Million 2014, and is projected to reach $722.7 Million ... to 2019. The global radiology information ...
    Breaking Medicine Technology:China Progesterone Market Investigation Report 2015-2019 2Investigation Report on China's Raloxifene Market, 2015-2019 2Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 2Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 3
    ... Boston Scientific,Corporation (NYSE: BSX ) ... COGNIS(TM),cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM),implantable ... platforms to treat heart failure and sudden ... multi-year research and development effort to provide,physicians ...
    ... CeloNova BioSciences, Inc.,("CeloNova"), leading and accelerating healthcare ... today announced breakthrough,results from the ATLANTA study ... Polyzene(R)-F at the 20th Annual International Symposium ... ), Corrado Tamburino, MD, President ...
    Cached Medicine Technology:Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death 2Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death 3Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death 4CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F 2
    (Date:9/3/2015)... ... September 03, 2015 , ... ... for LANDESK Management Suite customers, as part of the LANDESK One Partner ... IT, by delivering the best mobile user experience in remote access and control:, ...
    (Date:9/3/2015)... ... 2015 , ... Advice columnist, professional life coach and entrepreneur ... Wasting Your Time Blaming Others for Your Life.” , Released just in time ... obstacles by taking full responsibility for one’s life shares 15 important life lessons ...
    (Date:9/3/2015)... ... 03, 2015 , ... Girl’s Night Out to benefit Core Compassion Project will ... Kate Road in Monroe, North Carolina. The event food will be provided ... Kate Clyde’s offers off-premise catering and event services from casual to elegant. They are ...
    (Date:9/3/2015)... , ... September 03, 2015 , ... ... Intellicure, Inc., in its Annual Inc. 5000 list of fastest-growing private companies ... "only a tiny fraction of the nation's companies have demonstrated such remarkably consistent ...
    (Date:9/3/2015)... , ... September 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief executive ... top executive search firms in the healthcare industry, B. E. Smith has recently ...
    Breaking Medicine News(10 mins):Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 2Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 3Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 4Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3
    ... Solutions , , HOUSTON, June 5 The ... for seniors, with over 500,000 members, has established two ... Retirement Planning. , , These two new divisions ... members, with the goal of better educating and empowering ...
    ... ... Harley Street based clinic - The London Clinic. The contract marks the world,s first live ... ... , a leading provider of clinical workflow and integration technology for the health care sector ...
    ... ... the privacy minded individual. , ... London, England (PRWEB) June 5, 2009 -- Best Pills Inc is proud ... bestpills.co.uk., , ,The site is unique in its offering of popularly prescribed "discreet" ...
    ... Inc. (NYSE: NUS ) today announced the board ... share, which will be paid on June 25, 2009, to ... The Company , For 25 years, Nu Skin ... its comprehensive anti-aging product portfolio, independent business opportunity and corporate ...
    ... Ortho Biotech Oncology Research & Development, a unit ... it has entered into a five-year Cooperative Research and ... with Steven A. Rosenberg, M.D., Ph.D., chief, Surgery Branch, ... develop novel cell therapy technologies as potential treatments for ...
    ... Pennsylvania, June 4 , ... Australian Sponsored,Publication Practices From 2000-2005 , ... scientific, technical and,medical (STM) information products and services, ... guidelines for its pharmaceutical services,divisions when producing reprints, ...
    Cached Medicine News:Health News:Senior Citizens Bureau Creates New Resourceful Divisions 2Health News:Orion Health Live at Harley Street Clinic 2Health News:Orion Health Live at Harley Street Clinic 3Health News:Bestpills Launchs its New Online Pharmacy 2Health News:Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer 2Health News:Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer 3Health News:Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer 4Health News:Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications 2Health News:Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications 3
    The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
    ... cardiac markers are available on ... Cardiac Troponin I (cTnI) is ... sensitivity and specificity for myocardial ... soon following AMI. CK-MB (mass) ...
    ... For the quantitative determination of myoglobin concentration ... ELISA test is based on the principle ... The assay system utilizes a unique monoclonal ... on the myoglobin molecule. Mouse monoclonal anti-myoglobin ...
    Prolactin Radioimmunoassay...
    Medicine Products: